Related Experiment Video
Updated: Jun 13, 2026
07:53
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Vascular disrupting agents (VDAs) in anticancer therapy
Laura G M Daenen1, Jeanine M L Roodhart, Yuval Shaked
1Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Current Clinical Pharmacology
|April 22, 2010
Summary
Vascular disrupting agents (VDAs) target tumor blood vessels, causing collapse and necrosis. Combination therapies are being explored to prevent tumor regrowth from viable tissue rims.
Area of Science:
- Oncology
- Pharmacology
- Vascular Biology
Background:
- Vascular disrupting agents (VDAs) are a novel drug class targeting tumor vasculature.
- VDAs differ from antiangiogenic agents, specifically targeting abnormal tumor blood vessels.
- VDA administration induces rapid changes in tumor endothelial cells, leading to vascular collapse and tumor necrosis.
Purpose of the Study:
- To explore combination strategies for VDA therapy to overcome tumor regrowth.
- To investigate the molecular and cellular mechanisms of VDA response.
- To assess the clinical efficacy of VDAs in ongoing trials.
Main Methods:
- Preclinical models were used to design and test multiple drug combinations.
- Ongoing clinical trials, including phase III randomized trials, are evaluating VDA benefits.
Main Results:
- VDA therapy leads to tumor vascular collapse and central necrosis.
- Tumor repopulation from viable peripheral tissue is a key challenge.
- Preclinical studies show promising results for various combination strategies.
Conclusions:
- VDAs offer a unique approach to cancer treatment by targeting tumor vasculature.
- Combination therapies are crucial to enhance VDA efficacy and prevent tumor recurrence.
- Further clinical investigation is warranted to establish the full therapeutic potential of VDAs.
More Related Videos
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:35Cancer Cell Migration through Invadopodia
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...